Boulder, Colo., and Castres, France (October 25, 2016) - Array BioPharma (NASDAQ: ARRY) and Pierre Fabre announced today that results from the Phase 3 COLUMBUS trial of binimetinib and encorafenib in BRAF-mutant melanoma will be presented at the 2016 Society for Melanoma Research (SMR) Annual Congress in Boston, Massachusetts on November 9. Findings from COLUMBUS evaluating the combination of encorafenib plus binimetinib ("combination") in patients with unresectable or metastatic BRAF-mutant melanoma will be presented as an oral, late-breaking abstract. T

wo
data
analyses
from
the NEMO
Phase 3
trial
will also be presented
, which evaluated binimetinib in patients with
NRAS-
mutant melanoma.

COLUMBUS TRIAL DATA

Data from the Phase 3 study will be featured as an oral presentation during the late-breaking abstract session on Wednesday, November 9
from
10:00 - 1
0
:
15
A
M ET:

- Abstract 2617508: Results of COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

- Presenter: Keith T. Flaherty, M.D., Director of the Termeer Center for Targeted Therapy, Massachusetts General Hospital and Professor of Medicine, Harvard Medical School , Boston, Massachusetts

As reported in late September, 577 patients were randomized 1:1:1 to receive the combination of encorafenib plus binimetinib, encorafenib alone, or vemurafenib alone. In the analysis of the primary endpoint, the median PFS for patients treated with the combination of encorafenib plus binimetinib ("combination") was 14.9 months versus 7.3 months for patients treated with vemurafenib; HR (0.54), [95% CI 0.41-0.71], p